Could a second pill boost heart failure treatment?
NCT ID NCT07351864
First seen Jan 25, 2026 · Last updated Apr 28, 2026 · Updated 12 times
Summary
This study tests whether adding the drug finerenone to standard heart failure treatment (an SGLT2 inhibitor) can reduce deaths and hospital stays. Researchers will compare the combination against the standard drug alone in 60 adults aged 18-65 with newly diagnosed heart failure. The goal is to see if the combo is safer and more effective at controlling the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mansoura University Hospitals, Cardiology Department (Specialized Medical Hospital)
Al Mansurah, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.